Publications and presentations

AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.

June 4, 2011
PresentationFiclatuzumab

ASCO 2011: Phase 1b Study of Ficlatuzumab (AV-299), an Anti-Hepatocyte Growth Factor Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC

February 12, 2011
PublicationTivozanib

Development of second-generation VEGFR tyrosine kinase inhibitors: Current status

Authors: Pankaj Bhargava, Murray O. Robinson. Click here for link to article.

November 19, 2010
PresentationTivozanib

EORTC-NCI-AACR 2010: Tivozanib Biomarker Identifies Tumor-infiltrating Myeloid Cells Contributing to Tivozanib Resistance in Both Preclinical Models and Human Renal Cell Carcinoma

October 1, 2010
PresentationTivozanib

IKCS 2010: Effect of Hypertension, Nephrectomy, and Prior Treatment on the Efficacy of Tivozanib (AV-951) in a Phase 2 Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma

October 1, 2010
PresentationTivozanib

IKCS 2010: Activity of Tivozanib (AV-951) in Patients With Different Histologic Subtypes of Renal Cell Carcinoma

September 29, 2010
Publication

GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling

Authors: Ailin Bai, Kristan Meetze, Nhi Y. Vo, Sriram Kollipara, Elizabeth K. Mazsa, William M. Winston, Solly Weiler, Laura L. Poling, Ting Chen, Nesreen S. Ismail, Jinwei Jiang, Lorena Lerner, Jeno Gyuris, Zhigang Weng. Click here for link to article.

1 … 12 13 14 15

Looking for medical information? Contact our Medical Information Team at

AVEOmedicalinformation@aveooncology.com.